United Therapeutics Co. (NASDAQ:UTHR) Receives $392.00 Consensus PT from Brokerages

Shares of United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) have received an average rating of "Moderate Buy" from the twelve analysts that are currently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $392.00.

UTHR has been the topic of several research reports. HC Wainwright reaffirmed a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a research report on Monday. Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price target on the stock in a report on Monday, April 21st. UBS Group increased their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. StockNews.com cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday. Finally, JPMorgan Chase & Co. reduced their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st.

United Therapeutics Trading Down 1.2 %

Shares of UTHR stock traded down $3.68 on Friday, hitting $295.02. The stock had a trading volume of 386,583 shares, compared to its average volume of 441,666. United Therapeutics has a twelve month low of $260.41 and a twelve month high of $417.82. The company has a fifty day moving average price of $300.98 and a two-hundred day moving average price of $343.30. The firm has a market cap of $13.30 billion, a P/E ratio of 12.96, a PEG ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.29 by $0.34. The business had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. United Therapeutics's quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $6.17 EPS. On average, analysts expect that United Therapeutics will post 24.48 earnings per share for the current year.

Insider Transactions at United Therapeutics

In related news, Director Tommy G. Thompson sold 2,500 shares of the business's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares in the company, valued at $2,703,424. The trade was a 22.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Raymond Dwek sold 4,000 shares of the company's stock in a transaction on Monday, April 7th. The shares were sold at an average price of $284.55, for a total value of $1,138,200.00. Following the completion of the transaction, the director now directly owns 1,750 shares in the company, valued at approximately $497,962.50. This represents a 69.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 75,500 shares of company stock worth $24,245,880 over the last quarter. Company insiders own 11.90% of the company's stock.

Institutional Investors Weigh In On United Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Parallel Advisors LLC grew its stake in United Therapeutics by 2.8% during the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock worth $385,000 after purchasing an additional 30 shares during the period. Signaturefd LLC boosted its stake in United Therapeutics by 4.7% during the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock worth $234,000 after acquiring an additional 30 shares in the last quarter. Anchor Investment Management LLC grew its holdings in United Therapeutics by 12.0% in the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 30 shares during the period. Great Lakes Advisors LLC increased its stake in United Therapeutics by 1.6% in the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock valued at $697,000 after purchasing an additional 31 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund raised its holdings in shares of United Therapeutics by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock valued at $3,214,000 after purchasing an additional 33 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.